Traduction de «key factor 3 developing transversality » (Néerlandais → Français) :

Key factor 3 Developing transversality within the organisation ●● Ensuring optimal coordination between the
Key factor 3 Developing transversality within the organisation ●● Ensuring optimal coordination between the

manner ●● Informing the public optimally ●● Developing transversality (cooperation across
manner ●● Informing the public optimally ●● Developing transversality (cooperation across

Central to this endeavour are the six key factors which represent the FAMHP’s vision and ambition: ●● Recognition at national, European and international level ●● Developing partnerships with the healthcare
Central to this endeavour are the six key factors which represent the FAMHP’s vision and ambition: ●● Recognition at national, European and international level ●● Developing partnerships with the healthcare

Key factor 4 Developing partnerships with the healthcare sector ●● Determining common objectives and priorities with the sector (e.g. professional associations and industry) ●● Determining common objectives and priorities with patients’ associations and members of the public
Key factor 4 Developing partnerships with the healthcare sector ●● Determining common objectives and priorities with the sector (e.g. professional associations and industry) ●● Determining common objectives and priorities with patients’ associations and members of the public

These impacts however were more than offset by a number of positive factors, including: Marketing & Sales costs, which were lower by 0.4 percentage points due to productivity improvements partly offset by investments in growth areas; R&D costs, which decreased (improving +1.2 percentage points) as productivity savings funded continued investment in the development of differentiated generics; General & Administration costs, which decreased (+1.1 percentage points) due to ongoing cost reduction measures; and Other Income and Expenses, which were positive at 0.5 percentage points due to lower legal fees.
Cependant, ces impacts ont été plus que compensés par un certain nombre de facteurs positifs, notamment: une baisse de 0,4 point de pourcentage des coûts de Marketing et vente due à des gains de productivité en partie contrebalancés par des investissements dans des domaines en pleine croissance; une diminution des coûts de Recherche et développement (amélioration +1,2 point), des gains de productivité servant à financer des investissements continus dans le développement de génériques différenciés; un abaissement des coûts d’Administration et frais généraux (+1,1 point) grâce à des mesures continues de réduction des coûts; une progression de 0,5 point d'Autres produits et charges suite à une baisse des frais juridiques.

54. Thomas JK, Forrest A, Bhavnani SM et al: Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely lit patients during therapy.
54. Thomas JK, Forrest A, Bhavnani SM et al : Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely lit patients during therapy.

Key factors for the reduction included acquisitionrelated charges for the EBEWE Pharma integration (–0.7 percentage points), exceptional costs for termination of a co-development agreement (–0.8 percentage points) and provisions for settlement of Average Wholesale Pricing litigation in the US (–1.9 percentage points).
Les principaux facteurs de cette réduction sont des charges liées à l’intégration d’EBEWE Pharma (–0,7 point de pourcentage), des coûts exceptionnels pour la cessation d’un accord de codéveloppement (–0.8 point) et des provisions pour le règlement du litige concernant le prix de gros moyen aux Etats-Unis (–1.9 point).